Skip Navigation


NDT Advance Access originally published online on December 9, 2007
Nephrology Dialysis Transplantation 2008 23(1):11-17; doi:10.1093/ndt/gfm683
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/1/11    most recent
gfm683v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ahmed, M. S.
Right arrow Articles by Wong, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahmed, M. S.
Right arrow Articles by Wong, C. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Rituximab and nephrotic syndrome: a new therapeutic hope?

Muhammad Shahed Ahmed and Christopher F. Wong

Department of Nephrology, Aintree University Hospital Foundation Trust, Lower Lane, Liverpool L9 7AL, UK

Correspondence and offprint requests to: Dr Christopher F. Wong, Department of Nephrology, Aintree University Hospital Foundation Trust, Lower Lane, Liverpool L9 7AL, UK. Tel: +44-1515293356; Fax: +44-1515292420; E-mail: chriswong@doctors.org.uk

Keywords: focal segmental glomerulosclerosis; membranous; minimal change glomerulonephritis; nephrotic syndrome; rituximab

The first 150 words of the full text of this article appear below.



   Introduction
 
Nephrotic syndrome (NS) remains a therapeutic challenge to nephrologists, despite trials of different ranges of therapeutic regimens. Treatment of NS secondary to either primary glomerulonephritis (GN) or recurrence in renal transplantation remains controversial, as various immunosuppression and plasma exchange regimes have been advocated, with variable success and risk of severe toxic effects [1–17]. Rituximab (RIT) is a chimeric monoclonal antibody that acts by inhibiting CD20-mediated B-cell proliferation and differentiation. The CD20 antigen is a membranous protein found on B cells as well as on malignant cells such as in non-Hodgkin's lymphoma (NHL). It was first introduced in the late 1990s for the treatment of B cell NHL [18,19]. Since then, it has been used in over half a million patients with haematological malignancies, as first line and maintenance treatment. We reviewed the current literature to investigate the use of RIT in NS.

We searched . . . [Full Text of this Article]



   Rituximab in nephrotic syndrome secondary to idiopathic membranous glomerulonephritis
 


   Rituximab in nephrotic syndrome secondary to minimal change glomerulonephritis
 


   Rituximab in nephrotic syndrome secondary to focal segmental glomerulosclerosis
 


   Idiopathic membranous glomerulonephritis
 


   Focal segmental glomerulosclerosis
 


   Minimal Change Glomerulonephritis
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy
Ali El-Firjani, Stephanie Hoar, Jolanta Karpinski, Robert Bell, Marie-Josee Deschenes, and Greg A. Knoll
NDT 2008 23: 425. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 NDT PlusHome page
N. Printza, F. Papachristou, V. Tzimouli, A. Taparkou, and F. Kanakoudi-Tsakalidou
Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome
NDT Plus, October 1, 2009; 2(5): 435 - 436.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Coppo
Non-steroidal and non-cytotoxic therapies for nephrotic syndrome
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1793 - 1796.
[Full Text] [PDF]